age-related macular degeneration — TargetMol Chemicals

Cat No.	Product Name	Synonyms	Targets
T9928	Ranibizumab		VEGFR
	Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121, and VEGF165. Ranibizumab's ability to selectively target and n...		VEGFR
T13157	TG 100801	TG100801,TG 100572	VEGFR , Src
	TG 100801 is a dual inhibitor of VEGFr2 and Src family (Src and YES) kinases and is a candidate compound for the treatment of age-related macular degeneration (AMD).		VEGFR , Src
T2706	Palomid 529	P529,SG 00529	Apoptosis , mTOR
	Palomid 529 (SG 00529) has been used in trials studying the treatment of Age-Related Macular Degeneration.		Apoptosis , mTOR
T7493	AG-13958	AG-013958	VEGFR
	AG-13958 (AG-013958) (AG-013958), a potent VEGFR tyrosine kinase inhibitor, for the treatment of age-related macular degeneration.		VEGFR
T77600	Methyl-4-oxoretinoate		Apoptosis
	Methyl-4-oxoretinoate is a synthetic retinoid compound with anticancer compounds that can induce differentiation and apoptosis in cancer cells.Methyl-4-oxoretinoate is used in the treatment of acne, psoriasis, and other ...		Apoptosis
T28273L	OT-551 HCl	OT-551 HCl（627085-11-4 Free base）	NF-κB
	OT-551 HCl is an NF-Κb inhibitor, a disubstituted hydroxylamine with antioxidant properties can be used for the treatment of cataracts and age-related macular degeneration and geographic atrophy (GA).		NF-κB
T28273	OT-551	CPC 551,OT 551,CPC551,CPC-551
	OT-551, a NF-κB inhibitor, is used potentially for the treatment of cataracts and age-related macular degeneration.
T27670	JNJ-26076713	JNJ26076713
	JNJ-26076713, an orally active alpha V integrin antagonist, represents a potential therapeutic candidate for the treatment of macular edema, age-related macular degeneration, and proliferative diabetic retinopathy.
TP1390	CEP dipeptide 1
	CEP dipeptide 1, a potent angiogenic compound, exhibits robust activity in promoting angiogenesis. This compound is specifically implicated in the pathogenesis of age-related macular degeneration (AMD).
T39706	Pegaptanib sodium
	Pegaptanib sodium, an RNA aptamer specifically targeting vascular endothelial growth factor (VEGF)-165, holds great promise for investigating neovascular age-related macular degeneration (AMD).
T9695L	POT-4 acetate	POT-4 acetate (934461-40-2 free base)	Complement System
	POT-4 acetate inhibits Complement C3 activation. POT-4 acetate can be used for studies about age-related macular degeneration.		Complement System
T71988	Moxaverine hydrochloride
	Moxaverine hydrochloride is a derivative of papaverine, a phosphodiesterase inhibitor. Moxaverine has been studied in phase III of a clinical trial for the treatment of ocular blood flow in patients with age- related mac...
T36620	ALK4290	ALK4290
	ALK4290 (AKST4290) is a potent and orally actively CCR3 inhibitor, compound Example 2, with a Ki of 3.2 nM for hCCR3[1]. ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsoni...
T13157L	TG 100801 Hydrochloride		VEGFR
	TG 100801 Hydrochloride is a prodrug to treat age-related macular degeneration. TG 100572 is a inhibitor of multi-targeted kinase(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PD...		VEGFR
TP1464	Risuteganib hydrochloride
	Risuteganib hydrochloride is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order ...
T77016	Galegenimab
	Galegenimab (FHTR 2163; RG 6147; RO 7171009), an antibody fragment targeting High-temperature requirement A1 (HTRA1), is utilized in the research of age-related macular degeneration (AMD) [1].
T76887	Rinucumab
	Rinucumab (REGN 2176), a monoclonal antibody that acts as a PDGF inhibitor, holds potential for researching neovascular age-related macular degeneration [1].
T76210	POT-4 TFA
	POT-4 TFA (AL-78898A TFA), a derivative of Compstatin, effectively inhibits the activation of complement factor C3. This compound is utilized in research related to age-related macular degeneration [1] [2].
T74867	UBX1325
	UBX1325, a Bcl-xL inhibitor, enhances apoptosis in senescent cells, serving as an effective anti-aging agent. It holds potential for age-related eye disease research, including diabetic macular oedema (DME), age-related ...
T75156L	Bevasiranib sodium
	Bevasiranib sodium, an siRNA compound, targets and silences the genes responsible for producing vascular endothelial growth factor (VEGF). The suppression of VEGF, a critical factor in the development of choroidal neo-va...